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cific diagnosis and pre-visit medication use, the associa-
tion between quality of life measurements and change in
therapy was no longer significant. CONCLUSION: Pa-
tients with musculoskeletal disorders who perceive their
mental and physical health as poor and report greater
levels of functional limitations are more likely to receive
an additional medication during a medical encounter.
Since therapy change is also a function of specific patient
diagnosis, future analyses should evaluate self-rating
health scores and therapy change within patients with
specific diagnosis.
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Patient registries go beyond clinical trials with respect to
the assessment of long-term outcomes and measures of
effectiveness. OBJECTIVES: To assess the long-term
safety and effectiveness of cyclosporine (CyA) in a popu-
lation with severe RA. METHODS: All RA patients in
British Columbia treated with CyA between 1991 and
1997 were registered. Demographics and RA treatments
were prospectively collected. Joint count [JC], morning
stiffness [MS], fatigue duration and toxicity parameters
(systolic and diastolic blood pressure [SBP and DBP], and
serum creatinine [SCr]) were assessed monthly up to 84
months. Baseline and serial data were compared using
paired tests. Survival analysis was used to assess time to
CyA discontinuation. RESULTS: 133 severe RA patients
[100 (75%) female, median age 58 years (28–82), median
RA duration 13.5 years (2–54), 98% previous DMARD]
were evaluated. CyA treatment data included duration
(median 14 months, 2–84), dose changes (median 8,
3–42), and dose at cessation (mean 3.25 mg/kg/day, 1.2–
4.5). 27 (25%) received concomitant methotrexate ther-
apy. CyA discontinuation occurred in 37 (28%) patients
due to ineffectiveness (29) and toxicity (8). Significant re-
ductions occurred in JC up to 24 months (32%, 41%,
and 54% at 6, 12, and 24 months respectively; all P 
0.001), and in fatigue duration (55% and 71% at 24 and
36 months respectively; P  0.019 and 0.009). SBP,
DBP, and SCr were significantly elevated over baseline
values throughout treatment. Discontinuation followed a
bimodal pattern with most occurring between 10 and 20
months and a slower rate thereafter. CONCLUSIONS:
Longterm treatment with CyA appears to be effective for
severe RA however SBP, DBP and SCr are adversely af-
fected in most patients.
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OBJECTIVES: To determine the state-of-the-art in qual-
ity-of-life assessment associated with male sexual func-
tioning/erectile dysfunction. METHODS: Using Medline,
we identified assessment instruments and scales by search-
ing the keywords: “erectile dysfunction,” “impotence,”
“quality of life,” and “sexual dysfunction.” We focused
on scales published since 1980 in English with evidence
of validity and reliability. We then evaluated these scales
regarding their primary use, operationalization of do-
mains, and psychometric properties. RESULTS: We in-
cluded 19 instruments designed to measure aspects of
male sexual functioning. Instruments were classified by
their primary use into symptom measures (11), quality-
of-life measures (3), couple assessments (4-one of these
was also counted as a symptom measure), treatment sat-
isfaction questionnaires (1), and diagnostic tools (1).
Most measured the domains of sex drive, erection, and
orgasm, using different terms and approaches. Addition-
ally, the domains varied in how they were operational-
ized, with some instruments assessing frequency and
others measuring intensity. Psychometric data revealed
varying degrees of methodological sophistication. CON-
CLUSIONS: There are a variety of scales available for
the assessment of male sexual functioning and erectile
dysfunction. However, the development of these mea-
sures has been ad hoc, with relatively little uniformity in
terms of which domains are measured and how common
domains are operationalized. Most questionnaires are
symptom measures, which do not measure the conse-
quences of erectile dysfunction on quality of life. Conse-
quently, a new instrument to explicitly assess domains of
quality of life associated with erectile dysfunction, in ad-
dition to symptoms, would be a valued addition to the
literature in support of clinical practice and research.
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